Piper Sandler analyst Christopher Donat maintains Enfusion (NYSE:ENFN) with a Overweight and lowers the price target from $15 to $12.
AMETEK Q1 Outlook: Adj. EPS $1.38 – $1.42 Vs. $1.43 Estimate; Revenue Up Mid-Single Digits
"For the first quarter of 2023, overall sales are also expected to be up mid-single digits compared to the same period last year. Adjusted earnings in the quarter are anticipated to be in the range of $1.38 to $1.42
